BioCentury
ARTICLE | Clinical News

ATryn: Phase III started

August 4, 2014 7:00 AM UTC

LFB’s rEVO Biologics Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase III PRESERVE-1 trial to evaluate ATryn in about 120 pregnant women. Patients will receive an initial 250 mg ...